References
1. Toren A, Nagler A. Solitary pulmonary cholesteroloma, multiple xanthelasmas and lipemia retinalis complicating hypercholesterolemia after bone marrow transplantation. Bone Marrow Transplant 1996;18(2):457-9.
2. Coakley JC, Vervaart P, McKay MR. Factitious hyponatremia in a patient with cholestatic jaundice following bone marrow transplantation. Pathology 1986;18(1):158-9.
3. Turchin A, Wiebe D, Seely E, Graham T, Longo W, Soiffer R. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant. 2005;35(1):85-9.
4. Zidan H, Lo S, Wiebe D, Talano J, Alemzadeh Rr. Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft‐versus‐host disease of the liver. Pediatr Blood Cancer 2008;50(6):1280-1.
5. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994;57(10):1479-83.
6. Satterthwaite R, Aswad S, Sunga V, Shidban H, Bogaard T, Asai P, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation. 1998 Feb 15;65(3):446-9.
7. Chueh S-CJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003;76(2):375-82.
8. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002 Aug;43(8):1170-80.
9. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000;16(4):505-11.
10. Fellin R, Manzato E. Lipoprotein-X fifty years after its original discovery. Nutr Metab Cardiovasc Dis. 2019 Jan;29(1):4-8.
11. Nemes K, Åberg F, Gylling H, Isoniemi H. Cholesterol metabolism in cholestatic liver disease and liver transplantation: from molecular mechanisms to clinical implications. World J Hepatol. 2016 Aug 8;8(22):924-32.
12. Miida T, Hirayama S. Controversy over the atherogenicity of lipoprotein-X. Curr Opin Endocrinol Diabetes Obes. 2019 Apr;26(2):117-123.
13. Rosenson RS, Baker AL, Chow MJ, Hay RV. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology. 1990 May;98(5 Pt 1):1351-7.
14. Heinl RE, Tennant HM, Ricketts JC, Rice CR, Robinson CB, Sandesara PB, et al. Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease. J Clin Lipidol. Jan-Feb 2017;11(1):282-286..